Search company, investor...
Antios Therapeutics company logo

Antios Therapeutics

Founded Year



Series B - II | Alive

Total Raised


Last Raised

$75M | 1 yr ago

About Antios Therapeutics

Antios Therapeutics is an Atlanta, GA-based biopharmaceutical company focused on the development of antiviral therapies for unmet medical needs. Antios is advancing a curative regimen for chronic HBV, an unmet global health problem affecting over 250 million people worldwide, and a cause of chronic hepatitis, liver cirrhosis and liver cancer. ATI-2173 is its main oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV).

Headquarters Location

575 Pharr Road NE Unit 12260

Atlanta, Georgia, 30355,

United States

Missing: Antios Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Antios Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Antios Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Antios Therapeutics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Antios Therapeutics Patents

Antios Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Hepatitis
  • Virology
  • Animal viral diseases
patents chart

Application Date

Grant Date


Related Topics




Virology, Virus families, Molecular biology, Transcription factors, Animal virology


Application Date


Grant Date



Related Topics

Virology, Virus families, Molecular biology, Transcription factors, Animal virology



Latest Antios Therapeutics News

2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others -

Oct 14, 2022

Vir Biotechnology Inc Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant. Report Highlights The report provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 1, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 3 molecules, respectively. Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease). The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease) Reasons to Buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information about this report visit Source: Global Markets Direct

Antios Therapeutics Frequently Asked Questions (FAQ)

  • When was Antios Therapeutics founded?

    Antios Therapeutics was founded in 2018.

  • Where is Antios Therapeutics's headquarters?

    Antios Therapeutics's headquarters is located at 575 Pharr Road NE, Atlanta.

  • What is Antios Therapeutics's latest funding round?

    Antios Therapeutics's latest funding round is Series B - II.

  • How much did Antios Therapeutics raise?

    Antios Therapeutics raised a total of $200.4M.

  • Who are the investors of Antios Therapeutics?

    Investors of Antios Therapeutics include Domain Associates, Delos Capital, Lumira Ventures, CAM Capital, Aisling Capital and 18 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.